156 related articles for article (PubMed ID: 36856727)
1. Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
Foltynie T; Gandhi S; Gonzalez-Robles C; Zeissler ML; Mills G; Barker R; Carpenter J; Schrag A; Schapira A; Bandmann O; Mullin S; Duffen J; McFarthing K; Chataway J; Parmar M; Carroll C;
Brain; 2023 Jul; 146(7):2717-2722. PubMed ID: 36856727
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer.
Zeissler ML; Li V; Parmar MKB; Carroll CB
J Parkinsons Dis; 2020; 10(2):413-428. PubMed ID: 32116263
[TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
5. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.
Gonzalez-Robles C; Weil RS; van Wamelen D; Bartlett M; Burnell M; Clarke CS; Hu MT; Huxford B; Jha A; Lambert C; Lawton M; Mills G; Noyce A; Piccini P; Pushparatnam K; Rochester L; Siu C; Williams-Gray CH; Zeissler ML; Zetterberg H; Carroll CB; Foltynie T; Schrag A;
J Parkinsons Dis; 2023; 13(6):1011-1033. PubMed ID: 37545260
[TBL] [Abstract][Full Text] [Related]
6. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
7. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT.
Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC
Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
11. Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings.
Noor NM; Pett SL; Esmail H; Crook AM; Vale CL; Sydes MR; Parmar MKB
F1000Res; 2020; 9():1109. PubMed ID: 33149899
[TBL] [Abstract][Full Text] [Related]
12. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
13. Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials.
Noor NM; Love SB; Isaacs T; Kaplan R; Parmar MKB; Sydes MR
BMJ Open; 2022 Mar; 12(3):e055615. PubMed ID: 35273052
[TBL] [Abstract][Full Text] [Related]
14. How should we be using biomarkers in trials of disease modification in Parkinson's disease?
Vijiaratnam N; Foltynie T
Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279
[TBL] [Abstract][Full Text] [Related]
15. Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.
Berk S; Greco BL; Biglan K; Kopil CM; Holloway RG; Meunier C; Simuni T
J Parkinsons Dis; 2017; 7(4):685-693. PubMed ID: 29103052
[TBL] [Abstract][Full Text] [Related]
16. Progress towards therapies for disease modification in Parkinson's disease.
Vijiaratnam N; Simuni T; Bandmann O; Morris HR; Foltynie T
Lancet Neurol; 2021 Jul; 20(7):559-572. PubMed ID: 34146514
[TBL] [Abstract][Full Text] [Related]
17. Cognitive rehabilitation for Parkinson’s disease dementia: a study protocol for a pilot randomised controlled trial.
Hindle JV; Watermeyer TJ; Roberts J; Martyr A; Lloyd-Williams H; Brand A; Gutting P; Hoare Z; Edwards RT; Clare L
Trials; 2016 Mar; 17():152. PubMed ID: 27000036
[TBL] [Abstract][Full Text] [Related]
18. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).
Murray DD; Babiker AG; Baker JV; Barkauskas CE; Brown SM; Chang CC; Davey VJ; Gelijns AC; Ginde AA; Grund B; Higgs E; Hudson F; Kan VL; Lane HC; Murray TA; Paredes R; Parmar MK; Pett S; Phillips AN; Polizzotto MN; Reilly C; Sandkovsky U; Sharma S; Teitelbaum M; Thompson BT; Young BE; Neaton JD; Lundgren JD
Clin Trials; 2022 Feb; 19(1):52-61. PubMed ID: 34632800
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
20. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
